“Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals” (ClinicalTrials.gov Identifier: NCT01394796). This evidence concerns the gene DYRK1A and Cognitive impairment.